Sensorion Names GJB2 Hearing Loss Therapy as Lead Program; Ends OTOF Trial

The strategic shift signals that GJB2-related hereditary hearing loss — the most prevalent form of genetic deafness — is becoming a priority target in the emerging gene therapy landscape, while setbacks in OTOF programs highlight the difficulty of translating inner-ear gene...